These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 2119419

  • 1. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.
    Hoogerbrugge N, Mol MJ, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef AF, Birkenhäger JC.
    J Intern Med; 1990 Sep; 228(3):261-6. PubMed ID: 2119419
    [Abstract] [Full Text] [Related]

  • 2. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
    Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson SO, Berglund L, Lindén T, Sjöberg A, Bondjers G.
    J Intern Med; 1990 Sep; 228(3):241-7. PubMed ID: 2119417
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W.
    Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
    Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, Insull W, Pan HY.
    Atherosclerosis; 1990 Dec; 85(2-3):219-27. PubMed ID: 2129319
    [Abstract] [Full Text] [Related]

  • 5. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H, Naito C, Ito H, Kawamura M, Miyazaki S.
    Curr Med Res Opin; 1990 Dec; 12(2):100-7. PubMed ID: 2118022
    [Abstract] [Full Text] [Related]

  • 6. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
    Crepaldi G, Baggio G, Arca M, Avellone G, Avogaro P, Bittolo Bon G, Bompiani GD, Capurso A, Cattin L, D'Alŏ G.
    Arch Intern Med; 1991 Jan; 151(1):146-52. PubMed ID: 1898694
    [Abstract] [Full Text] [Related]

  • 7. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Douste-Blazy P, Fruchart JC.
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, Noseda G.
    Eur J Clin Pharmacol; 1990 Mar; 39(2):101-5. PubMed ID: 2123791
    [Abstract] [Full Text] [Related]

  • 10. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
    Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, Berkson DM, Farnham DJ, Wolfson PM, Colfer HT.
    Clin Cardiol; 1991 Feb; 14(2):146-51. PubMed ID: 1904333
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W, Bimmermann A, Schleicher J.
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [Abstract] [Full Text] [Related]

  • 12. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR.
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
    Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Takeuchi I.
    Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
    [Abstract] [Full Text] [Related]

  • 15. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 16. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
    Shafiq N, Bhasin B, Pattanaik S, Pandhi P, Venkateshan SP, Singh M, Malhotra S.
    Int J Clin Pharmacol Ther; 2007 Oct 01; 45(10):548-55. PubMed ID: 17966840
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
    Athyros VG, Papageorgiou AA, Demitriadis DS, Kontopoulos AG.
    Curr Med Res Opin; 2001 Oct 01; 17(4):267-72. PubMed ID: 11922400
    [Abstract] [Full Text] [Related]

  • 18. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
    Ditschuneit HH, Dreyer M, Dammann HG, Ditschuneit H.
    Med Klin (Munich); 1991 Mar 15; 86(3):142-8. PubMed ID: 1903497
    [Abstract] [Full Text] [Related]

  • 19. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N, Homma Y, Tamachi H, Shigematsu H, Hata Y, Goto Y.
    JAMA; 1987 Jun 12; 257(22):3088-93. PubMed ID: 3108527
    [Abstract] [Full Text] [Related]

  • 20. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H, Fujita H, Michishita I, Takeda M, Kajinami K, Koizumi J, Takeda R, Takegoshi T, Wakasugi T, Ueda K.
    Atherosclerosis; 1988 Aug 12; 72(2-3):183-8. PubMed ID: 3145745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.